Laxmi Dental's Q3 FY26 Earnings Call Transcript Released
Laxmi Dental Limited released its Q3 FY26 earnings call transcript. Revenue grew 7.1% YoY to ₹66 crore. EBITDA margin was 10.6%, PAT margin 3%. A ₹5.8 crore one-time impact was noted. Positive outlook due to India-US trade deal reducing tariffs and focus on digital dentistry initiatives.
The announcement is a transcript of an earnings call, providing detailed financial performance and management outlook. While it confirms growth and future potential, it does not contain new, material announcements that would drastically alter the company's valuation in the short term.
The company reported revenue growth, expressed confidence in future performance driven by strategic initiatives and positive trade developments (India-US tariff reduction), and provided segment-specific growth details.
Laxmi Dental Limited has released the transcript of its Q3 FY26 Earnings Conference Call, which was held on February 11, 2026. The call, organized by Elara Securities (India) Private Limited, discussed the company's unaudited financial results for the quarter and nine months ended December 31, 2025. Key management personnel, including Mr. Rajesh Khakhar (Chairperson and Whole-Time Director), Mr. Sameer Merchant (Managing Director and CEO), and Mr. Dharmesh Dattani (Chief Financial Officer), participated in the call. The transcript is also available on the company's website, www.laxmidentallimited.com.
During the call, the company reported a Q3 FY26 revenue of ₹66 crore, a 7.1% year-on-year growth from ₹61.7 crore in the same period last year. This growth was achieved despite a challenging global environment. The gross profit margin stood at 69.5%, with EBITDA and PAT margins at 10.6% and 3%, respectively. A one-time impact of ₹5.8 crore was recorded as an exceptional item due to new labor code requirements.
The management expressed confidence in future growth, driven by initiatives such as promoting digital dentistry, AI implementation, product launches, and network expansion. The recent India-US trade deal, leading to a reduction in tariffs from 50% to 25%, is expected to positively impact export volumes and profitability, particularly for the US market which contributed approximately 20% of revenues in FY25. The company anticipates further tariff reductions to 18% in the future.
Segment-specific performance highlighted a 10.4% YoY growth in the dental lab business, with international labs showing robust 25% YoY growth. The aligner solution business remained stable at ₹16.4 crore, with expectations of improvement in Q4 FY26. Scanner sales saw a significant 46% YoY growth, reaching ₹6.4 crore, as the company focuses on increasing digital penetration in the Indian market. The pediatric dental business, Kids-e-Dental, grew by 7.2% YoY to ₹5.9 crore, with expectations of accelerated growth upon securing CE certification.
For the nine months ended FY26, revenue from operations reached ₹203.9 crore, a 14.3% growth. EBITDA stood at ₹29.9 crore, and profit after tax was ₹18.8 crore with a margin of 9.2%. The company is debt-free, leading to a sharp reduction in finance costs.
What to do with a filing like this
Laxmi Dental Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laxmi Dental Limited. Read the original for the full detail.